These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 18524997)

  • 1. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.
    Malinowski HJ; Westelinck A; Sato J; Ong T
    J Clin Pharmacol; 2008 Aug; 48(8):900-8. PubMed ID: 18524997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety of medications].
    Claude JR
    Ann Pharm Fr; 1999 Mar; 57(2):147-52. PubMed ID: 10365471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
    Ruisinger JF; Backes JM; Gibson CA; Moriarty PM
    Am J Cardiol; 2009 Feb; 103(3):393-4. PubMed ID: 19166695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of factors associated with dose differences between Japan and the United States.
    Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
    Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Availability and usage of new antibacterial drugs in Europe.
    Ziv G
    J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1122-8. PubMed ID: 7216885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Objectives and organization of the International Conference on Harmonization].
    Juillet Y
    Ann Pharm Fr; 1999 Mar; 57(2):137-42. PubMed ID: 10365469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving pediatric dosing through pediatric initiatives: what we have learned.
    Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
    Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The CORONA study].
    Metra M; Zacá V; Nodari S; Cas LD; Maggioni AP
    G Ital Cardiol (Rome); 2008 Apr; 9(4):229-33. PubMed ID: 18543792
    [No Abstract]   [Full Text] [Related]  

  • 16. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
    Chang Y; Burckart GJ; Lesko LJ; Dowling TC
    J Clin Pharmacol; 2013 Sep; 53(9):962-6. PubMed ID: 23832278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual review of newly approved drugs.
    Kupecz D
    Nurse Pract; 1997 Jan; 22(1):136, 138, 140 passim. PubMed ID: 9004315
    [No Abstract]   [Full Text] [Related]  

  • 20. Policy implications of drug importation.
    Palumbo FB; Mullins CD; Slagle AF; Rizer J
    Clin Ther; 2007 Dec; 29(12):2758-67. PubMed ID: 18201594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.